AAVXF:OTCMKTS
Abivax SA
139,00 US$
0,00%
(0,00) 1 d
9 juli, 09:30:01 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för AAVXF …
Börsvärde
6,86 md
Genomsn. vol.
0,00
Volym
0,00
52v högst
139,00 US$
52v lägst
71,26 US$
Beta
3,09
Utestående aktier
87,53 mn
Antal anställda
98
Börsvärde
6,86 md
Genomsn. vol.
0,00
Volym
0,00
52v högst
139,00 US$
52v lägst
71,26 US$
Beta
3,09
Utestående aktier
87,53 mn
Antal anställda
98
Nyheter och artiklar
Från webbkällor och nyhetspartner
https://www.dars.gov.et/
·
för 5 dagar sedan
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Om Abivax SA
VdMarc de Garidel | Hartmut J. Ehrlich
Anställda98
Grundades4 dec. 2013
Huvudkontor-
Sektor-
Webbplatsabivax.com